Abstract. Background. In acute ischemic stroke (AIS), more than 1,000 substances with known neuroprotective effects have been studied, but their effectiveness is considered insufficiently convincing. In 2018, Ukraine launched the release of a new free radical scavenger Xavron (active ingredient — edaravone), which since 2001 has been successfully prescribed in ...
Edaravone, a novel free radical scavenger, demonstrates neuroprotective effects by inhibiting vascular endothelial cell injury and ameliorating neuronal damage in ischemic brain models. The present study was undertaken to verify its therapeutic efficacy following acute ischemic stroke. We performed a multicenter, randomized, placebo-controlled, double-blind study on acute ischemic stroke patients ...
Materials of the XXI International Scientific and Practical Conference “Interdisciplinary Issues in Modern Neurology”, April 22-24, Truskavets, Ukraine. Considerable attention was paid to the problematic aspects of management of patients with acute ischemic stroke. Within the framework of separate scientific symposium was held a discussion about the possibilities of modern ...
Background: A free radical scavenger, edaravone, which has been used for the treatment of ischemic stroke, was reported to cause acute kidney injury (AKI) as a fatal adverse event. The aim of the present study was to clarify whether edaravone is associated with AKI in patients with acute ischemic stroke. ...
Effect of Edaravone on Favorable Outcome in Patients with Acute Cerebral Large Vessel Occlusion: Subanalysis of RESCUE-Japan Registry (Neurol. Med. Chir. (Tokyo), 2015 March; 55(3)) Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5) (Journal of Stroke and Cerebrovascular Diseases, 2017, ...
In 2019, «Yuria-Pharm» announced the year for the fight against thrombocytopenia. Regarding this company, an appropriate program was started, in which cancer and hematologic departments throughout Ukraine received recombinant human thrombopoietin (EMAPLUG) as charitable aid for patients with thrombocytopenia. Many readers of the medical newspaper “News of Medicine and Pharmacy” ...